Alzheimer's disease

Roche, AC Immune's tau-blocking drug flops in Alzheimer's as biotech's shares halved
Roche, AC Immune's tau-blocking drug flops in Alzheimer's as biotech's shares halved
Fierce Biotech
Roche
AC Immune
Alzheimer's disease
semorinemab
Flag link:
Seattle-based Athira, aiming for tough Alzheimer's and Parkinson's targets, raises $204M fo
Seattle-based Athira, aiming for tough Alzheimer's and Parkinson's targets, raises $204M fo
Endpoints
Athira Pharma
IPOs
Alzheimer's disease
Parkinson's Disease
Flag link:
Cassava Sciences Announces Positive Results In Phase 2 Trial Of New Alzheimer’s Drug
Cassava Sciences Announces Positive Results In Phase 2 Trial Of New Alzheimer’s Drug
Forbes
Cassava Sciences
clinical trials
Alzheimer's disease
sumifilam
Flag link:
An old Vertex drug gets new life as an Alzheimer's treatment, but human studies still far off
An old Vertex drug gets new life as an Alzheimer's treatment, but human studies still far off
Endpoints
Vertex Pharmaceuticals
Alzheimer's disease
VX-765
Flag link:
Athira Aims for the Nasdaq to Advance Alzheimer’s Drug to Phase 2 Tests
Athira Aims for the Nasdaq to Advance Alzheimer’s Drug to Phase 2 Tests
Xconomy
Athira Pharma
Alzheimer's disease
clinical trials
ATH-1017
Flag link:
Alzheon returns, with a $47 million NIH grant and one last shot at a pivotal PhIII Alzheimer’s success
Alzheon returns, with a $47 million NIH grant and one last shot at a pivotal PhIII Alzheimer’s success
Endpoints
Alzheon
NIH
grants
Alzheimer's disease
ALZ-801
Flag link:
Biogen nabs speedy FDA review for controversial Alzheimer’s drug
Biogen nabs speedy FDA review for controversial Alzheimer’s drug
Fierce Biotech
Biogen
aducanumab
Eisai
FDA
Alzheimer's disease
priority review
Flag link:
AbbVie cans Voyager Alzheimer’s, Parkinson’s gene therapy pacts
AbbVie cans Voyager Alzheimer’s, Parkinson’s gene therapy pacts
Fierce Biotech
AbbVie
Alzheimer's disease
Parkinson's Disease
Voyager Therapeutics
Flag link:
Roche doubles down on Tau
Roche doubles down on Tau
EP Vantage
Roche
anti-tau antibodies
UCB Pharma
UCB01017
Alzheimer's disease
Flag link:
Scientists get closer to blood test for Alzheimer’s disease
Scientists get closer to blood test for Alzheimer’s disease
Stat
diagnostics
Alzheimer's disease
Eli Lilly
Flag link:
Alzheimer’s catalysts round off a year dominated by Biogen
Alzheimer’s catalysts round off a year dominated by Biogen
EP Vantage
Alzheimer's disease
Roche
Eli Lilly
AC Immune
Biohaven
Cortexyme
Biogen
Flag link:
AC Immune's Tau Vaccine for Alzheimer's Advanced into Phase Ib/II Clinical Trials
AC Immune's Tau Vaccine for Alzheimer's Advanced into Phase Ib/II Clinical Trials
BioSpace
AC Immune
clinical trials
ACI-35.030
Alzheimer's disease
Flag link:
Biogen and Eisai trial drug in asymptomatic Alzheimer’s disease
Biogen and Eisai trial drug in asymptomatic Alzheimer’s disease
Pharmaforum
Biogen
Eisai
Alzheimer's disease
amyloid
BAN2401
clinical trials
Flag link:
Alzheimer’s Drugs on Verge of Becoming Mainstream Medicine, but Early Intervention Still is Needed
Alzheimer’s Drugs on Verge of Becoming Mainstream Medicine, but Early Intervention Still is Needed
BioSpace
Alzheimer's disease
drug development
diagnostics
aducanumab
Biogen
Flag link:
Biogen Alzheimer’s Drug in FDA’s Court Following Completion of Filing
Biogen Alzheimer’s Drug in FDA’s Court Following Completion of Filing
Xconomy
Biogen
FDA
aducanumab
Alzheimer's disease
Flag link:
Amylyx Pharmaceuticals nabs $30M for ALS, Alzheimer's work
Amylyx Pharmaceuticals nabs $30M for ALS, Alzheimer's work
Fierce Biotech
Amylyx Pharmaceuticals
funding
ALS
Alzheimer's disease
Flag link:
Presented with upbeat Alzheimer's agitation data, FDA sees another 'breakthrough' in Axsome's AXS-05
Presented with upbeat Alzheimer's agitation data, FDA sees another 'breakthrough' in Axsome's AXS-05
Endpoints
Axsome Therapeutics
Alzheimer's disease
AXS-05
major depressive disorder
Flag link:
After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer's Drug
After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer's Drug
BioSpace
Denali Therapeutics
Sanofi
DNL747
ALS
Alzheimer's disease
DNL788
clinical trials
Flag link:
Can a small biotech successfully tackle an Everest climb like Alzheimer’s? Athira has $85M and some influential backers ready to give it a shot
Can a small biotech successfully tackle an Everest climb like Alzheimer’s? Athira has $85M and some influential backers ready to give it a shot
Endpoints
Alzheimer's disease
Athira Pharma
clinical trials
Flag link:
Lilly wins first-ever FDA approval for drug that can spot Alzheimer's 'tau tangles'
Lilly wins first-ever FDA approval for drug that can spot Alzheimer's 'tau tangles'
BioPharma Dive
Eli Lilly
FDA
Alzheimer's disease
R&D
tau tangles
Tauvid
imaging
diagnostics
Flag link:

Pages